Fixed Irbesartan/Amlodipine Combination: Efficacy and Safety of the Use of Four Dosing Regimens in Patients With Arterial Hypertension

被引:0
作者
Kobalava, Zh. D. [1 ]
机构
[1] PFUR, Moscow 117198, Russia
关键词
combination therapy; four dosing regimens; irbesartan/amlodipine; arterial hypertension; DOSE COMBINATIONS; MG MONOTHERAPY; OPEN-LABEL; PHASE-III; THERAPY; MULTICENTER; AMLODIPINE; VALSARTAN; MODERATE; PROFILE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: to assess efficacy, safety, and tolerability of 4 fixed irbesartan/amlodipine combinations in hypertensive patients resistant to monotherapy with 150 mg irbesartan or 5 mg amlodipine in a 16 week prospective open uncontrolled randomized multicenter study. Material and methods. We included in this study 158 patients with essential arterial hypertension (AH) (mean age 57.6 +/- 10.1 years, 119 women) receiving monotherapy with 150 mg irbesartan (n=78; 49.4%) or 5 mg amlodipine (n=80; 50.6%). Patients not achieving target arterial pressure (AP) <140/90 mm (n = 149) Hg were given fixed irbesartan/amlodipine combination 150/5 mg. If target AP was not achieved patients were randomized to 150/10 or 300/5 mg combinations. If necessary after 4 more weeks these doses were increased to maximal (300/10 mg). Thus 4 fixed irbesartan/amlodipine combinations were used: 150/5, 150/10, 300/5, 300/10 mg. Primary criterion of efficacy was portion of patients with target AP at last visit. Safety was assessed by presence of unfavorable events, clinical and laboratory parameters. Results. After 16 weeks 43, 23.5, 23.5 and 8.7% of patients received 150/5, 150/10, 300/5 and 300/10 mg combinations, respectively. At final visit 93.3% of patients had AP <140/90 mm Hg. Mean AP lowering in the total group was -21.7 +/- 9.1/-10.9 +/- 10.8 mm Hg (p<0.0001). There were 2 cases of ankle edema (5.7%) but no withdrawals due to unfavorable events. There were no differences between 4 dosing regimens in laboratory and clinical parameters of safety and tolerability. Conclusion. In patients with AH not achieving target AP on monotherapy with irbesartan 150 or amlodipine 5 mg administration of irbesartan/amlodipine combination with possibility of dose titration using 4 fixed combinations was effective in 93.3% of patients, resulted in significant systolic and diastolic AP lowering in all therapeutic groups, was well tolerated and safe.
引用
收藏
页码:15 / +
页数:6
相关论文
共 15 条
  • [1] Ali K, 2009, VASC HEALTH RISK MAN, V5, P587
  • [2] Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study
    Allemann, Yves
    Fraile, Belen
    Lambert, Michel
    Barbier, Michaela
    Ferber, Philippe
    Izzo, Joseph L., Jr.
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2008, 10 (03) : 185 - 194
  • [3] I-COMBINE Study: Assessment of Efficacy and Safety Profile of Irbesartan/Amlodipine Fixed-Dose Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled With Amlodipine 5 mg Monotherapy: A Multicenter, Phase III, Prospective, Randomized, Open-Label With Blinded-End Point Evaluation Study
    Bobrie, Guillaume
    [J]. CLINICAL THERAPEUTICS, 2012, 34 (08) : 1705 - 1719
  • [4] I-ADD Study: Assessment of Efficacy and Safety Profile of Irbesartan/Amlodipine Fixed-Dose Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled With Irbesartan 150 mg Monotherapy: A Multicenter, Phase III, Prospective, Randomized, Open-Label With Blinded End Point Evaluation Study
    Bobrie, Guillaume
    [J]. CLINICAL THERAPEUTICS, 2012, 34 (08) : 1720 - 1734
  • [5] Chobanian AV., 7 REPORT JOINT NATL
  • [6] Go A. S., 2013, EFFECTIVE APPROACH H, DOI [10.1161/HYP.0000000000000003, DOI 10.1161/HYP.0000000000000003]
  • [7] 2013 ESH/ESC Guidelines for the management of arterial hypertension
    Taylor, Jennifer
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 (28) : 2108 - 2109
  • [8] Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document
    Mancia, Giuseppe
    Laurent, Stephane
    Agabiti-Rosei, Enrico
    Ambrosioni, Ettore
    Burnier, Michel
    Caulfield, Mark J.
    Cifkova, Renata
    Clement, Denis
    Coca, Antonio
    Dominiczak, Anna
    Erdine, Serap
    Fagard, Robert
    Farsang, Csaba
    Grassi, Guido
    Haller, Hermann
    Heagerty, Anthony
    Kjeldsen, Sverre E.
    Kiowski, Wolfgang
    Mallion, Jean Michel
    Manolis, Athanasios
    Narkiewicz, Krzysztof
    Nilsson, Peter
    Olsen, Michael H.
    Rahn, Karl Heinz
    Redon, Josep
    Rodicio, Jose
    Ruilope, Luis
    Schmieder, Roland E.
    Struijker-Boudier, Harry A. J.
    van Zwieten, Pieter A.
    Viigimaa, Margus
    Zanchetti, Alberto
    [J]. JOURNAL OF HYPERTENSION, 2009, 27 (11) : 2121 - 2158
  • [9] A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension
    Morgan, T
    Anderson, A
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2002, 15 (06) : 544 - 549
  • [10] Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy
    Oparil, Suzanne
    Giles, Thomas
    Ofili, Elizabeth O.
    Pitt, Bertram
    Seifu, Yodit
    Hilkert, Robert
    Samuel, Rita
    Sowers, James R.
    [J]. JOURNAL OF HYPERTENSION, 2011, 29 (01) : 161 - 170